{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06117709",
            "orgStudyIdInfo": {
                "id": "23-187"
            },
            "organization": {
                "fullName": "Dana-Farber Cancer Institute",
                "class": "OTHER"
            },
            "briefTitle": "Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing",
            "officialTitle": "Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP): Development, Usability, and Acceptability Testing",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "integrated-smartphone-technology-to-alleviate-malignant-pain-i-stamp-testing"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-04-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-31",
            "studyFirstSubmitQcDate": "2023-10-31",
            "studyFirstPostDateStruct": {
                "date": "2023-11-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Andrea Enzinger, MD",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Dana-Farber Cancer Institute"
            },
            "leadSponsor": {
                "name": "Dana-Farber Cancer Institute",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "The Fund for Innovation in Cancer Informatics",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.",
            "detailedDescription": "The goal of this study is to develop and refine I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), an electronic health record-integrated mobile health (mHealth) application designed to support advanced cancer patients and care teams in pain management.\n\nThe research study procedures include screening for eligibility, surveys, and interviews. It is expected that up to 73 participants will take part in this research study. Activities 1-3 are non-interventional and will be used to collect data for application development.\n\nActivity 4: This activity will be interventional and will be added with a future amendment."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Cancer",
                "Pain"
            ],
            "keywords": [
                "Advanced Cancer",
                "Pain management",
                "Opioid pain management"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 73,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "I-STAMP Testing",
                    "type": "EXPERIMENTAL",
                    "description": "Study procedures will be conducted as follows:\n\nActivities 1-3: Data Collection for application development\n\nActivity 4: To be added with future amendment",
                    "interventionNames": [
                        "Behavioral: I-STAMP"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "I-STAMP",
                    "description": "A patient-facing smartphone application that hosts participants' analgesic and laxative medications, provides pain-specific psychoeducation, collects patient reported outcomes, and provides feedback to participant symptoms.",
                    "armGroupLabels": [
                        "I-STAMP Testing"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Usability",
                    "description": "Patients will complete a validated 10-item system usability scale (SUS) with total scores ranging from 0-100, where a score of 100 being the best possible usability score.",
                    "timeFrame": "2 weeks"
                },
                {
                    "measure": "E-scale Acceptability",
                    "description": "Patients will rate overall acceptability of the application using a modified acceptability e-scale. This 6-item measure asks patients to rate the app on ease of use, understandability, enjoyment, helpfulness, time spent, and overall satisfaction, on a 1 to 5 Likert scale. Items are summed to for a total score, ranging from 6 to 30 with 30 being the highest acceptability score.",
                    "timeFrame": "2 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria for Participants (Activities 1a, 2a, 3a):\n\n* Age \u2265 21 years\n* Current or previous diagnosis of advanced cancer\n* Current or previous experience with cancer pain\n\nExclusion Criteria for Participants (Activities 1a, 2a, 3a):\n\n* Inability to understand, speak, or read English\n* Any condition that would impede the patient's ability to complete study procedures such as visual impairment or significant cognitive impairment as determined by the participant's treating provider.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Andrea Enzinger, MD",
                    "role": "CONTACT",
                    "phone": "617-582-7335",
                    "email": "Andrea_Enzinger@dfci.harvard.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Andrea Enzinger, MD",
                    "affiliation": "Dana-Farber Cancer Institute",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Dana Farber Cancer Institute",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Andrea Enzinger, MD",
                            "role": "CONTACT",
                            "phone": "617-582-7335",
                            "email": "andrea_enzinger@dfci.harvard.edu"
                        },
                        {
                            "name": "Andrea Enzinger, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \\[contact information for Sponsor Investigator or designee\\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "Data can be shared no earlier than 1 year following the date of publication",
            "accessCriteria": "DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M27664",
                    "name": "Laxatives",
                    "relevance": "LOW"
                },
                {
                    "id": "M5651",
                    "name": "Cathartics",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                }
            ]
        }
    },
    "hasResults": false
}